Search Results - "Uhlar, Clarissa M."

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial by Facon, Thierry, Kumar, Shaji K, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Tromp, Brenda, Delioukina, Maria, Vermeulen, Jessica, Usmani, Saad Z

“…In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with…”
Get full text

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

“…The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled…”
Get full text

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial by Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z, Kumar, Shaji, Bahlis, Nizar J, Hulin, Cyrille, Orlowski, Robert Z, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, Van Rampelbergh, Rian, Uhlar, Clarissa M, Wang, Jianping, Kobos, Rachel, Gries, Katharine S, Fastenau, John, Weisel, Katja

“…To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs)…”
Get full text

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials by Usmani, Saad Z, Nahi, Hareth, Plesner, Torben, Weiss, Brendan M, Bahlis, Nizar J, Belch, Andrew, Voorhees, Peter M, Laubach, Jacob P, van de Donk, Niels W C J, Ahmadi, Tahamtan, Uhlar, Clarissa M, Wang, Jianping, Feng, Huaibao, Qi, Ming, Richardson, Paul G, Lonial, Sagar

“…Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a…”
Get full text

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 by Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, Girgis, Suzette

“…Background Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma (RRMM) who…”
Get full text

Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma by Facon, Thierry, Kumar, Shaji K, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, Perrot, Aurore, Weisel, Katja, Raje, Noopur, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Wang, Jianping, Rampelbergh, Rian Van, Uhlar, Clarissa M, Vermeulen, Jessica, Duran, Joana, Borgsten, Fredrik, Usmani, Saad Z

“…This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared…”
Get full text

Serum amyloid A, the major vertebrate acute‐phase reactant by Uhlar, Clarissa M., Whitehead, Alexander S.

“…The serum amyloid A (SAA) family comprises a number of differentially expressed apolipoproteins, acute‐phase SAAs (A‐SAAs) and constitutive SAAs (C‐SAAs)…”
Get full text

Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study by Robinson, Jr, Donald W, Cormier, Janice N, Zhao, Ning, Uhlar, Clarissa M, Revicki, Dennis A, Cella, David

“…Clinical and health-related quality of life (HRQoL) information was analyzed to determine: (a) patient-reported signs, symptoms, and functioning, (b) HRQoL…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Evolution of the serum amyloid A (SAA) protein superfamily by Uhlar, C M, Burgess, C J, Sharp, P M, Whitehead, A S

“…The serum amyloid A (SAA) superfamily comprises a number of genes and proteins characterized from a range of mammalian species. The majority of members…”
Get more information

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA by Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Zweegman, Sonja

“…In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd)…”
Get full text

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies by Touzeau, Cyrille, Krishnan, Amrita Y, Moreau, Philippe, Perrot, Aurore, Usmani, Saad Z, Manier, Salomon, Cavo, Michele, Martinez Chamorro, Carmen, Nooka, Ajay K, Martin, Thomas G, Karlin, Lionel, Leleu, Xavier, Bahlis, Nizar J, Besemer, Britta, Pei, Lixia, Stein, Sarah, Wang Lin, Shun Xin, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Miao, Xin, Uhlar, Clarissa, Chastain, Katherine, Garfall, Alfred

“…Teclistamab is a B‑cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of patients with triple-class exposed…”
Get full text

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma by Miao, Xin, Wu, Liviawati S., Wang Lin, Shun Xin, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Verona, Raluca, Pei, Lixia, Su, Yaming, Ouellet, Daniele, Garfall, Alfred L., Krishnan, Amrita Y., Usmani, Saad, Girgis, Suzette, Zhou, Honghui

Get full text

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1 by Cortes-Selva, Diana, Casneuf, Tineke, Vishwamitra, Deeksha, Stein, Sarah, Perova, Tatiana, Skerget, Sheri, Ramos, Elena, van Steenbergen, Laure, De Maeyer, Dries, Boominathan, Rengasamy, Lau, Onsay, Davis, Cuc, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa M., Kobos, Rachel, Goldberg, Jenna D., Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad, Bahlis, Nizar Jacques, Van De Donk, Niels WCJ, Verona, Raluca

Get full text

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study by Kumar, Shaji K., Facon, Thierry, Usmani, Saad Z., Plesner, Torben, Orlowski, Robert Z., Touzeau, Cyrille, Basu, Supratik, Bahlis, Nizar J., Goldschmidt, Hartmut, O'Dwyer, Michael E., Venner, Christopher P., Weisel, Katja, Hulin, Cyrille, Karlin, Lionel, Preis, Meir, Broyl, Annemiek, Renwick, William, Hansson, Markus, Krevvata, Maria, Wang, Jianping, Van Rampelbergh, Rian, Ukropec, Jon, Uhlar, Clarissa M., Kobos, Rachel, Perrot, Aurore

“…Introduction: Daratumumab (DARA) is a human, CD38-targeting, IgG1κ monoclonal antibody approved as monotherapy in relapsed/refractory multiple myeloma (RRMM)…”
Get full text

Use of the acute phase serum amyloid A2 ( SAA2) gene promoter in the analysis of pro- and anti-inflammatory mediators: differential kinetics of SAA2 promoter induction by IL-1 β and TNF- α compared to IL-6 by Uhlar, Clarissa M, Grehan, Sharon, Steel, Diana M, Steinkasserer, Alexander, Whitehead, Alexander S

“…A cytokine responsive construct, pGL2-SAA2pt, was generated by cloning the acute phase promoter of human serum amyloid A2 ( SAA2) upstream of a luciferase…”
Get full text

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia by Bahlis, Nizar, Facon, Thierry, Usmani, Saad Z., Kumar, Shaji K., Plesner, Torben, Orlowski, Robert Z., Touzeau, Cyrille, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael E, Venner, Christopher P, Weisel, Katja C., Krevvata, Maria, Pei, Huiling, Wang, Jianping, Van Rampelbergh, Rian, Ukropec, Jon, Uhlar, Clarissa M., Kobos, Rachel, Perrot, Aurore

“…▪ Introduction: Daratumumab (DARA) is a human, CD38-targeted, IgG1κ monoclonal antibody approved as monotherapy in heavily pretreated relapsed/refractory…”
Get full text

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma by Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred L., van de Donk, Niels W.C.J., Nahi, Hareth, San-Miguel, Jesus, Oriol, Albert, Nooka, Ajay K., Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar J., Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Pei, Lixia, Trancucci, Danielle, Verona, Raluca I., Girgis, Suzette, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa M., Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, Krishnan, Amrita Y.

“…Introduction: Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors…”
Get full text

MM-339: Effect of Lenalidomide (R) ± Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies by Moreau, Philippe, Facon, Thierry, Usmani, Saad Z., Dimopoulos, Meletios, Kumar, Shaji, Plesner, Torben, Goldschmidt, Hartmut, Reece, Donna, Orlowski, Robert Z., Perrot, Aurore, Leiba, Merav, Chari, Ajai, San-Miguel, Jesus, Cook, Gordon, Iida, Shinsuke, Pei, Huiling, Rampelbergh, Rian Van, Uhlar, Clarissa M., Renaud, Thomas, Ukropec, Jon, Kobos, Rachel, Bahlis, Nizar

“…Daratumumab (D), is approved as monotherapy and combination therapy for MM. We report an analysis of patients who discontinued R±d in the D-Rd arm of the MAIA…”
Get full text

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA) by Facon, Thierry, Kumar, Shaji K., Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming, Usmani, Saad Z.

“…Abstract Introduction Lenalidomide-based therapies are a standard of care for patients with newly diagnosed, transplant-ineligible MM. Daratumumab (DARA) is a…”
Get full text